Urinary and reproductive system infection
Conditions
Interventions
The SGLT2i observation group:None
The group not using SGLT2i:None
Sponsors
Qilu Hospital of Shandong University (Qingdao)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Voluntary signing of the informed consent form; 2. Age >= 18 years old; 3. Gender not limited; 4. Patients diagnosed with the corresponding disease according to the above guidelines; 5. Patients who, based on the judgment of the treating doctor, need to start treatment with SGLT2 inhibitors or non-SGLT2 inhibitors; 6. Expected survival period >= 1 year; 7. Willing and able to comply with the research visit schedule.
Exclusion criteria
Exclusion criteria: 1. Those allergic to SGLT2 inhibitors; 2. Pregnant or lactating women; 3. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m^2; 4. Severe liver dysfunction (Child-Pugh C grade); 5. Active malignant tumors; 6. Immunodeficiency conditions (such as HIV infection, after organ transplantation, long-term use of high-dose glucocorticoids); 7. Acute infection within 4 weeks prior to enrollment; 8. Participating in other interventional clinical trials simultaneously; 9. Long-term or short-term urinary catheterization; 10. Judged by the investigator as not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence rate of symptomatic urinary tract infection;Incidence of genital infections; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of severe infection events;Recurrent infection rate;The duration and type of antibiotic use;The rate of treatment interruption due to infection;Other adverse events (such as hypoglycemia, ketoacidosis, dehydration, etc.); | — |
Countries
China
Contacts
Public ContactQingya Yang
Qilu Hospital of Shandong University (Qingdao)
Outcome results
None listed